Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antiviral Effect of BZF961 in HCV Patients
NCT01825980Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BZF961 in hepatitis C (HCV), sponsored by Novartis. Started Mar 2013; status: completed.
02
Drugs
BZF961
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01825980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01825980.